# A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.

> **NCT05598268** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ImmVira Pharma Co. Ltd** · enrollment: 74 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Lung Cancer
- Liver Cancer
- Lymphoma
- Mesothelioma of Pleura

## Interventions

- **BIOLOGICAL:** T3011

## Key facts

- **NCT ID:** NCT05598268
- **Lead sponsor:** ImmVira Pharma Co. Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598268, "A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05598268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*